By Michael McCaughan
If you want to market a new pharmaceutical or vaccine ingredient in the US, you should consult a copy of the 2007 Food & Drug Administration Amendments Act.
FDAAA Impact Analysis: Year One
The RPM Report’s analysis of the fi rst year under FDA’s new law makes one fact clear: sponsors seeking approval for never-before-marketed ingredients need to assume the new tools will apply to them.